Cancer Biologics Market
Cancer Biologics Market - Global Industry Assessment & Forecast
#
Pages:
149
Base Year:
2024
Jun - 2024
Format:
Report Code:
VMR-2506
Segments Covered
By
Drug Class Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins , CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), Interferons (IFN), Gene Therapy, Other Drug Classes
-
By
Application Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, Other Applications
-
By
End Use Hospitals, Cancer Center, Academics & Research Institutes
-
By
Region North America , Europe , Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2035 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 106.2 Billion |
 Revenue 2035:
|
USD 161.4 Billion |
 Revenue CAGR
(2025 - 2035): |
8.50% |
Fastest Growing Region (2025 -
2035)
|
Asia Pacific |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
-
Executive Dashboard
- Strategic Imperatives
-
Premium Insights
- Top 3 Trends to Watch
- Demand and Supply Trends
- Top 3 Strategies Followed by Major Players
- Top 3 Predictions by Vantage Market Research
- Top Investment Pockets
- Insights from Primary Respondents
-
Global Cancer Biologics Market - Segment Analysis
- Overview
- Global Cancer Biologics Market, 2016 - 2028 (USD Million)
-
Global Cancer Biologics Market - by Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
-
Global Cancer Biologics Market - by Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
-
Global Cancer Biologics Market - by End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
-
Global Cancer Biologics Market - by region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Market comparative analysis
-
North America Cancer Biologics Market - Segment Analysis
- Overview
- North America Cancer Biologics Market, 2016 - 2028 (USD Million)
-
North America Cancer Biologics Market, by Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
-
North America Cancer Biologics Market, by Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
-
North America Cancer Biologics Market, by End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
-
North America Cancer Biologics Market, by Country
- U.S.
- U.S. Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- U.S. Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- U.S. Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- U.S. Cancer Biologics Market, By Drug Class
- Canada
- Canada Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Canada Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Canada Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Canada Cancer Biologics Market, By Drug Class
- Mexico
- Mexico Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Mexico Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Mexico Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Mexico Cancer Biologics Market, By Drug Class
- U.S.
-
Europe Cancer Biologics Market - Segment Analysis
- Overview
- Europe Cancer Biologics Market, 2016 - 2028 (USD Million)
-
Europe Cancer Biologics Market, by Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
-
Europe Cancer Biologics Market, by Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
-
Europe Cancer Biologics Market, by End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
-
Europe Cancer Biologics Market, by Country
- Germany
- Germany Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Germany Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Germany Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Germany Cancer Biologics Market, By Drug Class
- UK
- UK Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- UK Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- UK Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- UK Market, By Drug Class
- France
- France Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- France Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- France Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- France Cancer Biologics Market, By Drug Class
- Spain
- Spain Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Spain Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Spain Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Spain Cancer Biologics Market, By Drug Class
- Italy
- Italy Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Italy Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Italy Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Italy Cancer Biologics Market, By Drug Class
- BENELUX
- BENELUX Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- BENELUX Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- BENELUX Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- BENELUX Cancer Biologics Market, By Drug Class
- Rest of Europe
- Rest Of Europe Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Rest Of Europe Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Rest Of Europe Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Rest Of Europe Cancer Biologics Market, By Drug Class
- Germany
-
Asia Pacific Cancer Biologics Market - Segment Analysis
- Overview
- Asia Pacific Cancer Biologics Market, 2016 - 2028 (USD Million)
-
Asia Pacific Cancer Biologics Market, by Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
-
Asia Pacific Cancer Biologics Market, by Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
-
Asia Pacific Cancer Biologics Market, by End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
-
Asia Pacific Cancer Biologics Market, by Country
- China
- China Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- China Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- China Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- China Cancer Biologics Market, By Drug Class
- Japan
- Japan Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Japan Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Japan Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Japan Cancer Biologics Market, By Drug Class
- India
- India Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- India Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- India Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- India Cancer Biologics Market, By Drug Class
- South Korea
- South Korea Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- South Korea Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- South Korea Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- South Korea Cancer Biologics Market, By Drug Class
- South East Asia
- South East Asia Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- South East Asia Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- South East Asia Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- South East Asia Cancer Biologics Market, By Drug Class
- Rest of Asia Pacific
- Rest of Asia Pacific Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Rest of Asia Pacific Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Rest of Asia Pacific Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Rest of Asia Pacific Cancer Biologics Market, By Drug Class
- China
-
Latin America Cancer Biologics Market - Segment Analysis
- Overview
- Latin America Cancer Biologics Market, 2016 - 2028 (USD Million)
-
Latin America Cancer Biologics Market, by Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
-
Latin America Cancer Biologics Market, by Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
-
Latin America Cancer Biologics Market, by End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
-
Latin America Cancer Biologics Market, by Country
- Brazil
- Brazil Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Brazil Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Brazil Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Brazil Cancer Biologics Market, By Drug Class
- Argentina
- Argentina Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Argentina Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Argentina Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Argentina Cancer Biologics Market, By Drug Class
- Rest of Latin America
- Rest of Latin America Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Rest of Latin America Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Rest of Latin America Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Rest of Latin America Cancer Biologics Market, By Drug Class
- Brazil
-
Middle East & Africa Cancer Biologics Market - Segment Analysis
- Overview
- Middle East & Africa Cancer Biologics Market, 2016 - 2028 (USD Million)
-
Middle East & Africa Cancer Biologics Market, by Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
-
Middle East & Africa Cancer Biologics Market, by Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
-
Middle East & Africa Cancer Biologics Market, by End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
-
Middle East & Africa Cancer Biologics Market, by Country
- GCC Countries
- GCC Countries Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- GCC Countries Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- GCC Countries Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- GCC Countries Cancer Biologics Market, By Drug Class
- South Africa
- South Africa Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- South Africa Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- South Africa Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- South Africa Cancer Biologics Market, By Drug Class
- Rest of Middle East & Africa
- Rest of Middle East & Africa Cancer Biologics Market, By Drug Class
- By Monoclonal Antibodies
- By Cancer Growth Inhibitors
- By Vaccines
- By Recombinants Proteins
- By CAR-T Cells
- By Angiogenesis Inhibitors
- By Interleukins (IL)
- By Interferons (IFN)
- By Gene Therapy
- By Other Drug Classes
- Rest of Middle East & Africa Cancer Biologics Market, By Application
- By Blood Cancer
- By Lung Cancer
- By Breast Cancer
- By Colorectal Cancer
- By Prostate Cancer
- By Gastric Cancer
- By Ovarian Cancer
- By Skin Cancer
- By Liver Cancer
- By Other Applications
- Rest of Middle East & Africa Cancer Biologics Market, By End Use
- By Hospitals
- By Cancer Center
- By Academics & Research Institutes
- Rest of Middle East & Africa Cancer Biologics Market, By Drug Class
- GCC Countries
-
Key Market Dynamics
- Introduction
- Market Drivers
- Market Restraints
- Market Opportunities
- Porter's Five Forces Analysis
- PEST Analysis
- Regulatory Landscape
- Technology Landscape
- Regional Market Trends
-
COVID 19 Impact Analysis
- Key strategies undertaken by companies to tackle COVID-19
- Short term dynamics
- Long term dynamics
-
Marketing Stratagy Analysis
- Marketing Channel
- Direct Marketing
- Indirect Marketing
- Marketing Channel Development Trends
-
Competative Landscape
- Competition Matrix - 2021
- Company Market Share Analysis - 2021
- Key Company Activities, 2018 - 2021
- Strategic Developments - Heat Map Analysis
- Company Offering Evaluation
- Company Regional Presence Evaluation
-
Company Profiles
- Abbott Laboratories (U.S.)
- Angel Pharmaceuticals (China)
- Amgen Inc. (U.S.)
- AstraZeneca (UK)
- BioNTech (Germany)
- Bristol-Mayer Squibb Company (U.S.)
- Dr. Reddy's Laboratories (India)
- Duality Biologics (China)
- Eli Lilly and Company (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Key Primary Respondents - VERBATIM
- Discussion Guide
- Customization Offered
- Annexure
- List of Figures
- List of Tables
- List of Abbreviations
Vantage Market
Research | 26-Jun-2024
FAQ
Frequently Asked Question
What is the global demand for Cancer Biologics in terms of revenue?
-
The global Cancer Biologics valued at USD 106.2 Billion in 2024 and is expected to reach USD 161.4 Billion in 2035 growing at a CAGR of 8.50%.
Which are the prominent players in the market?
-
The prominent players in the market are Abbott Laboratories (U.S.), Angel Pharmaceuticals (China), Amgen Inc. (U.S.), AstraZeneca (UK), BioNTech (Germany), Bristol-Mayer Squibb Company (U.S.), Dr. Reddy's Laboratories (India), Duality Biologics (China), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 8.50% between 2025 and 2035.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Cancer Biologics include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Cancer Biologics in 2024.
